Hairy cell leukemia: update and current therapeutic approach

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Hairy cell leukaemia (HCL) is a rare, indolent B-cell malignancy.
• Standard treatment involves purine nucleoside analogues (pentostatin, cladribine), achieving high initial remission rates.
• A significant proportion of patients develop relapsed or refractory disease.

Purpose of the Study:

• To review the pathogenesis of HCL.
• To discuss current standard therapeutic approaches.
• To explore novel targeted therapies for HCL, including BRAF inhibitors and antibody-based treatments.

Main Methods:

• Review of existing literature on HCL pathogenesis and treatment.
• Analysis of clinical trial data for novel HCL therapies.
• Discussion of molecular targets, including BRAFV600E mutation.

Main Results:

• Purine analogue therapy is effective for initial HCL treatment but often leads to relapse.
• Relapsed/refractory HCL poses treatment challenges.
• BRAFV600E mutation is nearly universal in HCL, supporting targeted therapy development.
• Vemurafenib (BRAF inhibitor) and antibody-based therapies show promising results in ongoing trials.

Conclusions:

• Targeted therapies, particularly BRAF inhibitors, represent a significant advancement for HCL treatment.
• Monoclonal antibodies and immunotoxins are also emerging as effective options.
• Further research and clinical trials are crucial to optimize treatment strategies for HCL, especially in relapsed/refractory settings.